Hyperpolarized 13-C-pyruvate

Phase 2Small molecule

Hyperpolarized 13-C-pyruvate is one of 138 small molecule programs targeting Primary Brain Neoplasm. It is currently in Phase 2.

Indications

Total Trials

Active Trials

137

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary Brain NeoplasmRecruiting

GliomaRecruiting

MeningiomaRecruiting

Prostate CancerWithdrawn

Thyroid CancerRecruiting

MRI ScanActive, not recruiting

Primary Brain NeoplasmPhase 1

Recruiting

GliomaPhase 1

Recruiting

MeningiomaPhase 1

Recruiting

Prostate CancerPhase 2

Withdrawn

Thyroid CancerPhase 1

Recruiting

MRI ScanPhase 2

Active, not recruiting

Competition

Competitive Landscape

348 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Phase 3

20 2

Cabometyx

Bristol-Myers Squibb

Phase 3

12 3

Glucophage

EMD Serono

Phase 3

14 4

Zejula

GGlaxo Dba Glaxosmithkline

Phase 3

10 5

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

7 6

Lutetium Lu-177 PNT2002

JJonsson Comprehensive Cancer Center

Phase 3

4 7

Hyperpolarized 13-C-pyruvate

MM.D. Anderson Cancer Center

Phase 2

2 8

Rhpsma-7.3 (18f)

BBlue Earth Diagnostics

Phase 3

4 9

HC-1119

HHinova Pharmaceuticals Inc.

Phase 3

2 10

Trexall

Jazz Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

MRI Scan

NCT04258462

Q1 2027

Phase 1Recruiting

Glioma

NCT04540107

Q2 2027

Phase 1Recruiting

Thyroid Cancer

NCT04589624

Q3 2027

Phase 1Recruiting

Meningioma

NCT06014905

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance

Recruiting·UUniversity of California, San Francisco·Phase 2·NCT03933670·60 enrolled

Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT03581500

Ovarian Cancer1 trial

Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging

Suspended·MM.D. Anderson Cancer Center·Phase 1·NCT05866679·30 enrolled

Central Nervous System Tumor1 trial

Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors

Completed·—·Phase 1·NCT03565367·9 enrolled

Thyroid Cancer1 trial

An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT04589624·42 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma

Terminated·ZZhen Wang, MD·Phase 2·NCT04565327·7 enrolled

5 more indications

Glioma1 trial

Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma

Recruiting·SSusan Chang·Phase 1·NCT04540107·300 enrolled

MRI Scan1 trial

Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors

Active, not recruiting·ZZhen Wang, MD·Phase 2·NCT04258462·54 enrolled

Meningioma1 trial

Pilot/Phase I Study of Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma

Recruiting·JJavier Villaneuva-Meyer, MD·Phase 1·NCT06014905·50 enrolled

Pancreatic1 trial

Pilot Study Using Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopic Imaging in Patients With Pancreatic Cysts Undergoing Surgical Resection

Suspended·MM.D. Anderson Cancer Center·Phase 1·NCT05873699·20 enrolled

Primary Brain Neoplasm1 trial

Hyperpolarized Pyruvate Imaging of Glioma: Imaging-Pathological Correlation

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT03830151·13 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Hyperpolarized 13-C-pyruvate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hyperpolarized 13-C-pyruvate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hyperpolarized 13-C-pyruvate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — M.D. Anderson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MM.D. Anderson Cancer Center

Hyperpolarized 13-C-pyruvate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Q3 2027

Trials by Indication[1]

Prostate Cancer2 trials

Ovarian Cancer1 trial

Central Nervous System Tumor1 trial

Thyroid Cancer1 trial

Pancreatic Ductal Adenocarcinoma1 trial

Glioma1 trial

MRI Scan1 trial

Meningioma1 trial

Pancreatic1 trial

Primary Brain Neoplasm1 trial

References

Drug Info

Quick Facts

Related News